Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Omthera Begins Phase 3 Enrollment

By Drug Discovery Trends Editor | August 16, 2011

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced that the first patient has been enrolled in its ESPRIT (Epanova combined with a Statin in Patients with HypertRiglycerIdemia to Reduce Non-HDL CholesTerol) Phase 3 clinical trial of Epanova, in patients with hypertriglyceridemia (TG level ?200 and < 500 mg/dL) despite treatment with a statin. The trial has been granted a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration.

Epanova, a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), is Omthera’s lead compound, currently in development as a prescription omega-3 free fatty acid for the treatment of patients with very high triglycerides (?500 mg/dL).  The Company’s Pivotal Phase 3 EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for this indication, which received SPA approval in November 2010, is ongoing, and will form the basis for filing a new Drug Application (“NDA”) with the U.S. Food & Drug Administration.  The results of the ESPRIT trial are not required for regulatory approval, but rather, if positive, would serve to expand the use of Epanova to a larger patient population.

The Phase 3 ESPRIT trial will be a six-week, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of add-on Epanova to statin therapy in patients with persistent hypertriglyceridemia despite statin therapy and who remain at high risk for cardiovascular disease.  The primary objective is to evaluate the efficacy of adding Epanova (2g or 4g daily) to statin monotherapy for lowering Non-HDL cholesterol (“Non-HDL-C”). Secondary objectives are to evaluate the safety of the Epanova and statin combination therapies, and to evaluate the effects of the combination therapies on other lipids and lipoproteins.  The trial is expected to enroll 642 subjects and will be conducted at approximately 100 sites in the U.S. 

Principal investigator for the ESPRIT study, Dr. Stephen Nicholls, Assistant Professor of Molecular Medicine and the Cardiovascular Director of the Cleveland Clinic Coordinating Center for Clinical Research and a consultant for Omthera Pharmaceuticals, noted, “Millions of Americans treated with statins, are still at risk for cardiovascular events.  Non-HDL-C is an important target of drug therapy for patients on a statin with TG between 200 and 500 mg/dL.  The results of this trial, if positive, could further support the use of omega-3 free fatty acids as a treatment for these patients.”

Dr. Michael Davidson, Chief Medical Officer and co-Founder of Omthera, stated, “The development of Epanova, which has the potential to become the best in class omega-3 fatty acid, is well underway.  Data generated earlier this year demonstrated that Epanova has superior bioavailability compared to the market leader, Lovaza®, and our EVOLVE trial, intended to support our planned NDA filing, has been actively enrolling subjects.  Today, with the initiation of the ESPRIT trial, we have now taken a further step to potentially expand the indication to include patients with persistent hypertriglyceridemia and high risk for cardiovascular disease, who are on statin therapy, for which there are currently no approved prescription omega-3 drugs.”

Date: August 15, 2011
Source: Omthera Pharmaceuticals, Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50